Docetaxel vs. vinorelbine in elderly patients with advanced non-small-cell lung cancer: A hellenic oncology research group randomized phase III study

Clinical Lung Cancer

Volumn 12, Issue 3, 2011, Pages 155-160

  Karampeazis, Athanasios ^a   Vamvakas, Lambros ^a   Agelidou, Athina ^a   Kentepozidis, Nikolaos ^a   Chainis, Kyriakos ^a   Chandrinos, Vassilis ^a   Vardakis, Nikolaos ^a   Pallis, Athanasios G ^a   Christophyllakis, Charalambos ^a   Georgoulias, Vassilis ^a,b  

^a Hellenic Oncology Research Group HORG   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Docetaxel; Elderly patients; First line treatment; Non small cell lung cancer (NSCLC); Phase III study; Vinorelbine

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; EARLY TERMINATION OF CLINICAL TRIAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GERIATRIC PATIENT; HUMAN; INOPERABLE CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; TAXOIDS; VINBLASTINE;

EID: 79959613188     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.015     Document Type: Article

References (29)

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95:1276-99. (Pubitemid 37160862)
2. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 85:365-76.
3. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-72. (Pubitemid 36395256)
4. Quoix E, Oster JP, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single agent therapy in patients aged 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer. J Clin Oncol 2010; 28:18S(suppl:abstr 2).
5. Yoshimura N, Kudoh S, Negoro S, et al. A phase II study of docetaxel in elderly patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19:532a(abstr 2093).
6. Hainsworth JD, Burris HA 3rd, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma: a Minnie Pearl Cancer Res Network phase II Trial. Cancer 2000; 89:328-33. (Pubitemid 30489880)
7. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24:3657-63. (Pubitemid 46630541)
8. Valerio M, Russo A, Latteri M, et al. Weeklydocetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study. Lung Cancer 2001; 34:S31-5.
9. Lilenbaum R, Schwartz M, Selgel L, et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 2001; 92:2158-63. (Pubitemid 32973327)
10. Lilenbaum R, Cashy J, Hensing T, et al. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 2008; 2:125-9. (Pubitemid 351323185)
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
12. National Cancer Institute. Common Toxicity Criteria for Adverse Events. Available at http://ctep.cancer.gov/protocoldevelopment/electronic-applications/ docs/ctcv20-4-30-992.pdf. Accessed April 13, 2011.
13. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-67. (Pubitemid 30035956)
14. Tang M, Davidoff A, Mullins C, et al. Chemotherapy (C) and survival among 21,441 elderly (E) patients (pts) with advanced (adv) NSCLC:Analysis of SEERMaedicare claim data 1997-2002. Proc Am Soc Clin Oncol 2008; 26:(abstr 8090).
15. Kelly K, Giarritta S, AkerleyW,et al. Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20:(abstr 1313).
16. Langer C, Manola J, Bernado P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94:173-81. (Pubitemid 34162751)
17. Langer C, Vangel J, Schiller D, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (-70). Proc Am Soc Clin Oncol 2003; 22:(abstr 2571).
18. Hensing T, Peterman A, Schell M, et al. The impact of age on toxicity, response rate, quality of life and survival in patients with advanced stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98:779-88. (Pubitemid 36959275)
19. Hainsworth J, Spigel D, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer. A randomized phase III trial of the Minnie Pearl Cancer Research Network. Cancer 2007; 110:227-34.
20. Hesketh P, Chansky K, Lau D, et al. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 2006; 1:537-544. (Pubitemid 47181401)
21. Stanley K. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65:25-32. (Pubitemid 10071592)
22. Albain K, Crowley J, LeBlank M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9:1617-26.
23. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:2529-36. (Pubitemid 30432518)
24. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005; 23:9113-19.
25. Kumar A, Soares H, Balducci L, et al. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute- sponsored cooperative groups. J Clin Oncol 2007; 25:1272-6. (Pubitemid 46646519)
26. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16:1582-7. (Pubitemid 28175784)
27. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology 2000; 14:221-7.
28. Basso U, Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care 2004; 13:424-33. (Pubitemid 40081560)
29. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25:1824-31. (Pubitemid 46860271)